Literature DB >> 17403189

Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.

Ana Monegal1, Miquel Navasa, Pilar Peris, Luisa Alvarez, Francesca Pons, Joan Rodés, Nuria Guañabens.   

Abstract

AIMS: A prospective study was carried out in 22 cirrhotic patients referred for orthotopic liver transplantation, in order to analyze serum osteoprotegerin (OPG) and RANKL levels and their relationship with metabolic bone disease.
METHODS: Serum levels of OPG and RANKL were measured in all patients as well as bone markers, serum parathyroid hormone and 25-hydroxyvitamin D levels. OPG and RANKL values were compared with those obtained in 29 healthy controls. Bone mineral density (BMD) of the lumbar spine and proximal femur was measured by dual X-ray absorptiometry and spinal X-rays were obtained to assess vertebral fractures.
RESULTS: Serum OPG levels were higher in cirrhotic patients than in controls (6.4+/-2 vs 2.7+/-0.7 pmol/l; P=0.001) and RANKL serum levels were lower in cirrhotic patients (0.215+/-0.6 vs 1.012+/-1.2 pmol/l; P=0.002), with an increased OPG:RANKL ratio when compared with the control group (280.3+/-334.5 vs 113+/-137.6; P=0.04). Ten patients had osteoporosis (45%) and up to 45% skeletal fractures. No differences were found in OPG levels between patients with and without osteoporosis by densitometric criteria or fractures. Negative correlations were found between OPG levels and femoral neck (R-0.46; P=0.03) and total hip BMD (R-0.48; P=0.025). By contrast, OPG values were not related to markers of bone turnover.
CONCLUSIONS: OPG values are elevated in cirrhotic patients before liver transplantation, particularly in those with low bone mass at the proximal femur.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403189     DOI: 10.1111/j.1478-3231.2007.01448.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

Review 1.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

Review 2.  Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?

Authors:  Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2010-08-16

Review 3.  Cholestasis and metabolic bone disease - a clinical review.

Authors:  Rudolf W Gasser
Journal:  Wien Med Wochenschr       Date:  2008

Review 4.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

5.  Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene Expression.

Authors:  Julio A Gutierrez; Krysten A Jones; Roxana Flores; Akul Singhania; Christopher H Woelk; Robert T Schooley; David L Wyles
Journal:  J Virol Antivir Res       Date:  2014-10-06

6.  Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol.

Authors:  C Santori; M Ceccanti; D Diacinti; M L Attilia; L Toppo; E D'Erasmo; E Romagnoli; M L Mascia; C Cipriani; A Prastaro; V Carnevale; S Minisola
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

7.  High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue.

Authors:  Núria Guañabens; Anna Enjuanes; Luisa Alvarez; Pilar Peris; Llorenç Caballería; M Jesús Martínez de Osaba; Dacia Cerdá; Anna Monegal; Francesca Pons; Albert Parés
Journal:  J Bone Miner Metab       Date:  2009-02-20       Impact factor: 2.626

8.  A study on OPG/RANK/RANKL axis in osteoporotic bile duct-ligated rats and the involvement of nitrergic and opioidergic systems.

Authors:  Amir Hossein Doustimotlagh; Ahmad Reza Dehpour; Shahroo Etemad-Moghadam; Mojgan Alaeddini; Sattar Ostadhadi; Abolfazl Golestani
Journal:  Res Pharm Sci       Date:  2018-06

9.  Bone microarchitecture and bone turnover in hepatic cirrhosis.

Authors:  R Wakolbinger; C Muschitz; G Scheriau; G Bodlaj; R Kocijan; X Feichtinger; J E Schanda; J Haschka; H Resch; P Pietschmann
Journal:  Osteoporos Int       Date:  2019-02-20       Impact factor: 4.507

10.  Prevalence and characteristics of bone disease in cirrhotic patients.

Authors:  Hale Gokcan; Meral Akdogan Kayhan; Sibel Ozbudak Demir; Sabite Kacar; Pinar Cam; Mustafa Kaplan; Rabia Daylak; Derya Oztuna; Sedef Özdal Kuran; Derya Ari
Journal:  Hepatol Forum       Date:  2020-05-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.